

TABLE OF CONTENTS

Book 11

Preface	i
Editorial Board	ii
Book 11 Panel	iii
Disclosure of Potential Conflicts of Interest	ix
Continuing Education and Program Evaluation Instructions	x
Book 11 Post Test	x
Role of ACCP	xv

Chronic Illnesses I

DIABETES IN CHILDREN AND ADOLESCENTS

Learning Objectives.....	1
Introduction.....	1
Pathophysiology.....	1
Screening.....	1
Abbreviations in This Chapter.....	2
Diagnosis.....	2
Therapeutic Goals.....	2
Quality Patient Care.....	3
New Drugs and New Drug Roles.....	3
Insulins.....	3
Noninsulin Subcutaneous Drugs.....	4
Oral Diabetes Drugs.....	4
Devices.....	4
Subcutaneous Injection Port.....	4
Insulin Pumps.....	4
Continuous Blood Glucose Monitors.....	5
Management Plans.....	5
Individualized Goals.....	5
Management of Type 1 DM.....	5
ADA Guidelines.....	5
Basal/Bolus Insulin Regimens.....	5
Newer Insulin Dose Adjustment Techniques.....	6
Insulin Pump Management.....	7
Lifestyle Modification.....	9
Management of Type 2 DM.....	9
MODY and Hybrid Diabetes.....	9
Monitoring.....	9
Adherence.....	11
Comorbidities.....	11

Clinical Practice.....	11
Patient Education.....	11
Conclusion.....	13
Annotated Bibliography.....	13
Self-Assessment Questions.....	17

MANAGEMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN

Learning Objectives	21
Introduction	21
Nomenclature	21
Epidemiology	21
Pathophysiology	21
Etiology and Pathogenesis	21
Abbreviations in This Chapter	22
Clinical Characteristics	22
Diagnosis	22
Prognosis	22
Quality Patient Care	22
Therapeutic Goals	22
Diabetes Management	22
Quality of Life	23
Goals of Therapy	23
Pharmacotherapy	23
Guidelines for Treatment	23
First-Tier Agents	23
Duloxetine	23
Opioids	25
Pregabalin	25
Tricyclic Antidepressants	25
Second-Tier Agents	25
Carbamazepine	25
Gabapentin	26
Lamotrigine	26
Tramadol	26
Venlafaxine	26
Topical Agents	26
Other Agents	26
Therapeutic Management Considerations	27
Onset of Effect	27
Dose Titration	27
Adverse Effects	27
Directions for Administration of	
Topical Agents	27
Special Populations	28
Comorbid Cardiac Disease	28
Comorbid Renal or Hepatic Impairment	28
Comorbid Depression	28

Elderly Patients	28
Modifying Therapy	28
Rational Polypharmacy	28
Drug Cost	29
Quality Improvement.....	29
Conclusion	29
Annotated Bibliography	29
Self-Assessment Questions	35

DIABETIC NEPHROPATHY

Learning Objectives	39
Introduction	39
Epidemiology	39
Pathophysiology of Diabetic Nephropathy	39
Abbreviations in This Chapter	40
Histologic Changes	40
Advanced Glycation End Products	40
Oxidative Stress	40
Glomerular Filtration Barrier Damage.....	40
Tubulointerstitial Injury	40
Renin-Angiotensin-Aldosterone System	40
Diagnosis	41
Stages of Diabetic Nephropathy.....	41
Pharmacotherapy.....	41
Antidiabetic Agents in the Treatment of Diabetic Nephropathy	43
Diabetes Control and Complications Trial	43
United Kingdom Prospective Diabetes Study	43
ACCORD and ADVANCE Trials	43
Antihypertensive Agents in the of Diabetic Nephrology	44
United Kingdom Prospective Diabetes Study	45
ADVANCE Trial	46
ACE Inhibitor Therapy in Type 1 and 2 DM	46
Irbesartan Diabetic Nephropathy Trial	46
RENAAL Study	46
Irbesartan in Type 2 DM and Microalbuminuria	46
Addition of Aldosterone Antagonists	47
Conclusion	47
Hypercholesterolemia Management	47
Protein Restriction	47
Management of End-Stage Diabetic Nephropathy	47
Dialysis	47
Transplantation	50
Prognosis	50
Controversies	50
ACE Inhibitors and ARBs in CKD	50
ACE Inhibitors and ARBs in Combination	50
Role of Aliskiren	51
High-Risk Patients	51
ACE Inhibitors and ARBs in African American Patients	51
The Pharmacist's Role.....	51
Annotated Bibliography	52
Self-Assessment Questions	55

Chronic Illnesses II

POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS

Learning Objectives.....	61
Introduction.....	61
Epidemiology and Risk Factors.....	61
Pathophysiology.....	61
Clinical Manifestations and Complications.....	61
Abbreviations in This Chapter.....	62
Diagnosis.....	62
Laboratory Evaluation.....	62
Role of Imaging Studies.....	62
Therapy for PMR and GCA.....	62
Corticosteroids.....	63
Empiric Dosing, Tapering, and Withdrawal.....	63
Management of Steroid Complications.....	64
Steroid-Sparing Agents	64
Azathioprine.....	64
Methotrexate.....	64
Infliximab.....	65
Antithrombotic Therapy.....	65
Role of the Pharmacist.....	65
Conclusion.....	66
Annotated Bibliography.....	66
Self-Assessment Questions	69

RHEUMATOID ARTHRITIS

Learning Objectives	73
Introduction	73
Pathophysiology	73
Role of Cytokines	73
Interleukin-6	73
Interleukin-7	73
Role of T Lymphocytes	73
Abbreviations in This Chapter	74
Role of B Lymphocytes	74
Diagnosis and Prognosis of RA	74
Comorbid Conditions	74
Cardiovascular Disease	74
Infection	75
Malignancy	75
Osteoporosis	75
Quality Patient Care	75
Pharmacotherapy	75
Biologic Response Modifiers	75
TNF Antagonists	75
Abatacept	79
B-Lymphocyte Therapies	79
Tocilizumab	80
Treatment Plan	80
Early Diagnosis and Treatment	80
Tuberculosis Screening, Prophylaxis, and Vaccination	81
Treatment During Pregnancy	81
Concomitant Therapy	82
Patient Education	82
Nonpharmacologic Measures	82
Smoking Cessation	82
Exercise	82
Occupational Therapy and Physical Therapy	82
Administering Drugs	83

Conclusion	83
Annotated Bibliography	83
Self-Assessment Questions	87
SYSTEMIC LUPUS ERYTHEMATOSUS	
Learning Objectives	91
Introduction	91
Pathophysiology	91
Diagnosis	91
Comorbid Conditions	91
Abbreviations in This Chapter	92
Prognosis	92
Therapeutic Goals/Outcomes	92
Quality Patient Care	92
Pharmacotherapy	92
Guidelines and Standards of Care	93
Disease Flare	94
Pharmacotherapy of Organ-Specific Manifestations	94
Lupus Nephritis	94
Neuropsychiatric Lupus	95
Antiphospholipid Syndrome	95
Skin Manifestations	95
Other SLE Manifestations	96
Adjunctive Therapy	96
Patient Education	96
Monitoring	96
General Monitoring Parameters	96
Organ-Specific Monitoring Parameters	96
General Disease Indices	97
Conclusion	99
Annotated Bibliography	99
Self-Assessment Questions	103

Chronic Illnesses III

METABOLIC SYNDROME

Learning Objectives.....	109
Overview.....	109
Associated Health Risks.....	109
Abbreviations in This Chapter.....	110
Pathophysiology.....	110
Obesity.....	110
Insulin Resistance.....	111
Characterization and Diagnosis.....	111
Abdominal Obesity.....	111
Atherogenic Dyslipidemia.....	112
Hypertension.....	112
Elevated Fasting Glucose.....	112
Prothrombotic and Pro-inflammatory State.....	112
Diagnostic Criteria.....	112
Management of Metabolic Syndrome.....	112
Role of the Pharmacist.....	112
Risk Assessment	113
Underlying Risk Factors.....	113
Abdominal Obesity.....	113
Metabolic Risk Factors.....	115
Atherogenic Dyslipidemia.....	115
Hypertension.....	117
Elevated Fasting Glucose.....	118
Prediabetes.....	118

Type 2 DM.....	119
Prothrombotic and Pro-inflammatory State.....	119
Other Agents That Target Metabolic Syndrome Pathophysiology.....	119
Rimonabant.....	119
Dual PPAR γ /PPAR α Agonists.....	120
Exenatide.....	120
Patient Education.....	120
Conclusion.....	120
Annotated Bibliography.....	120
Self-Assessment Questions	125

DISEASES OF THE AGING EYE

Learning Objectives	129
Introduction	129
Vision Screening and Assessment	129
Abbreviations in This Chapter	130
Age-Related Macular Degeneration	130
Pathophysiology, Classification, and Diagnosis	130
Clinical Outcome Measures	130
Risk Factors and Symptomology	132
Nonpharmacologic Treatment	132
Pharmacologic Treatment	133
Treatment of Nonneovascular AMD	133
Treatment of Neovascular AMD	133
Investigational Treatment	134
Glaucoma	134
Pathophysiology, Classification, and Diagnosis	134
Risk Factors	135
Nonpharmacologic Treatment	135
Pharmacologic Treatment	136
Treatment of Open-Angle Glaucoma	136
Investigational Treatment	136
Alternative and Complementary Medicine	137
Monitoring and Management of Complications	137
The Pharmacist's Role	138
Annotated Bibliography	138
Self-Assessment Questions	143

PHARMACOTHERAPY CONSIDERATIONS IN PALLIATIVE CARE

Learning Objectives.....	147
Introduction.....	147
Abbreviations in This Chapter.....	148
Polypharmacy.....	148
Drug Discontinuation.....	148
Considerations for Decision-Making	148
Disease Trajectory	148
Drug-Related Considerations	149
Potential for Adverse Outcomes	149
Criteria for Drug Use in Palliative Care	151
Pharmacokinetic Changes Occurring with Age and Disease.....	152
Drug-Drug Interactions.....	152
Drug Metabolism.....	152
Safe Discontinuation of Selected Drugs.....	153
Statins.....	153
Anticoagulation and Antiplatelet Agents.....	153
Other Agents.....	155
Goals of Care.....	155
Quality Improvement.....	155
Conclusion.....	156

Annotated Bibliography.....	156
Self-Assessment Questions.....	159